Neuberger Berman Group LLC Sells 99,477 Shares of Cytosorbents Co. (NASDAQ:CTSO)

Neuberger Berman Group LLC trimmed its stake in shares of Cytosorbents Co. (NASDAQ:CTSO) by 5.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,681,883 shares of the medical research company’s stock after selling 99,477 shares during the quarter. Neuberger Berman Group LLC owned approximately 3.08% of Cytosorbents worth $1,529,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Renaissance Technologies LLC grew its holdings in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Cytosorbents in the 4th quarter worth $99,000. Geode Capital Management LLC grew its holdings in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. Finally, Skylands Capital LLC increased its position in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after acquiring an additional 26,195 shares during the period. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Stock Up 3.4 %

CTSO stock opened at $0.97 on Friday. Cytosorbents Co. has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a market capitalization of $60.75 million, a price-to-earnings ratio of -2.70 and a beta of 1.17. The business’s 50 day moving average price is $1.06 and its two-hundred day moving average price is $1.02. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. As a group, analysts forecast that Cytosorbents Co. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CTSO. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, April 1st. StockNews.com began coverage on Cytosorbents in a research report on Friday. They issued a “hold” rating on the stock. Finally, HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Thursday, April 3rd. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Cytosorbents currently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.